SEARCH

SEARCH BY CITATION

References

  • Andrieu, J.M., Ifrah, N., Payen, C., Fermanian, J., Coscas, Y. & Flandrin, G. (1990) Increased risk of secondary acute nonlymphocytic leukaemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. Journal of Clinical Oncology, 8, 11481154.
  • Anonymous. (1998) Acute Leukaemia Forum'98. Advances and controversies in the biology and treatment of acute myelogenous leukaemia and myelodysplasia; symposium proceedings. San Francisco, California, USA. March 6, 1998. Leukaemia, 12, S1S56.
  • Belzi, D., Bidoli, E., Franceschi, S., Armiani, S., Pisani, P. & Geddas, M. (1997) Stima Dell'incidenza e Mortalità per Tumore nelle Regioni Italiane, 1st edn, pp. 1951. Grafiche Risma SNC, Rovereto in Piani.
  • Ben-Jehuda, D., Krichevsky, S., Caspi, O., Rund, D., Polliack, A., Abeliovich, O., Zelig, O., Yahalom, V., Paltiel, O., Or, R., Peretz, T., Ben-Neriah, S., Yehuda, O. & Rachmilewitz, E.A. (1996) Microsatellite instability and p53 mutations in therapy-related leukaemia suggest mutator phenotype. Blood, 88, 42964203.
  • Boivin, J.F. (1990) Second cancers and other late side effects of cancer treatment. Cancer, 65, 770775.
  • Brusamolino, E., Pagnucco, G. & Bernasconi, C. (1986) Acute leukemia occurring in a primary neoplasia (secondary leukemia). A review on biological, epidemiological and clinical aspects. Haematologica, 71, 6083.
  • Brusamolino, E., Anselmo, A.P., Klersy, C., Santoro, M., Orlandi, E., Pagnucco, G., Lunghi, F., Maurizi-Enrici, R., Baroni, C.D., Lazzarino, M., Mandelli, F. & Bernasconi, C. (1998) The risk of acute leukaemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy. a case–control study. Haematologica, 83, 812823.
  • Carey, R.W., Holland, J.F., Sheghe, P.R. & Grahams, S. (1967) Association of cancer of the breast and acute myelocytic leukaemia. Cancer, 20, 19881993.
  • Coleman, M.P., Bell, C.M.J. & Fraser, P. (1987) Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis: a population-based cohort study. British Journal of Cancer, 56, 349355.
  • Dastugue, N., Demur, C., Pris, F., Bugat, R., Attal, M., Bourrouillou, G. & Colombies, P. (1988) Association of the Philadelphia chromosome and 5q– in secondary blood disorder. Cancer Genetics and Cytogenetics, 30, 253259.
  • De Witte, T., Suciu, S., Peetermans, M., Fenaux, P., Strijckmans, P., Hayat, M., Jaksic, B., Selleslag, D., Zittoun, R., Dardenne, M., Solbu, G., Zwierzina, H. & Huus, P. (1995) Intensive chemotherapy for poor prognosis myelodyplasia (MDS) and secondary acute myeloid leukaemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukaemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukaemia, 9, 18051811.
  • Felix, C.A., Megonigal, M.D., Chervinsky, D.S., Leonard, D.G.B., Tsuchida, N., Kakati, S., Block, A.M., Fisher, J., Grossi, M., Salhany, K.I., Jani-Sait, S.N. & Aplan, P.D. (1998) Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukaemia. Blood, 91, 44514456.
  • Greene, M.H., Harris, E.L., Gershenson, D.M., Malkasian, Jr, G.D., Melton, L.J., Dembo, A.J., Bennett, J.M., Moloney, W.C. & Boice, Jr, J.D. (1986) Melphalan may be a more potent leukemogen than cyclophosphamide. Annals of Internal Medicine, 105, 360367.
  • Groupe Francais de Cytogenetique Hematologique. (1984) Chromosome analysis of 63 cases of secondary nonlymphoid blood disorders: a cooperative study. Cancer Genetics and Cytogenetics, 12, 95104.
  • Hawkins, M.M., Wilson, L.M., Stovall, M.A., Marsden, H.B., Potok, M.H., Kingston, J.E. & Chessells, J.M. (1992) Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. British Medical Journal, 304, 951958.
  • Hoyle, C.F., De Bastos, M., Wheatley, K., Wheatley, K., Sherrington, P.D., Fischer, P.J., Rees, J.K., Gray, R. & Hayhoe, F.G. (1989) AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. British Journal of Haematology, 72, 4553.
  • Kaldor, J.M., Day, N.E., Clarke, E.A., Van Leeuwen, F.E., Henry-Amar, M., Fiorentino, M.V., Bell, J., Pedersen, D., Band, P., Assouline, D., Koch, M., Choi, W., Prior, P., Blair, V., Langmark, F., Kirn, V.P., Neal, F., Peters, D., Pfeiffer, R., Karjalainen, S., Cuzick, J., Sutcliffe, S.B., Somers, R., Pellae-Cosset, B., Pappagallo, G., Fraser, P., Storm, H. & Stovall, M. (1990a) Leukemia following Hodgkin's disease. New England Journal of Medicine, 322, 713.
  • Kaldor, J.M., Day, N.E., Pettersson, F., Clarke, E.A., Pedersen, D., Mehnert, W., Bell, J.H., Høst, H., Prior, P., Karjalainen, S., Neal, F., Koch, M., Band, P., Choi, W., Kirn, V.P., Arslan, A., Zarèn, B., Belch, A.R., Storm, H., Kittelmann, B., Fraser, P. & Stovall, M. (1990b) Leukemia following chemotherapy for ovarian cancer. New England Journal of Medicine, 322, 16.
  • Kantarjian, H.M., Keating, M.J., Walters, R.S., Smith, T.L., Cork, A., McCredie, K.B. & Freireich, E.J. (1986) Therapy-related leukaemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. Journal of Clinical Oncology, 4, 17481757.
  • Koeffler, P. & Rowley, J. (1985) Therapy-related acute non-lymphocytic leukaemia. In: Neoplastic Diseases of the Blood (ed. by Wiernik, P., Canelos, G., Kyle, R. et al.), pp. 357384. Churchill Livingstone, New York.
  • Kony, S.J., De Vathaire, F., Chompret, A., Shamsaldim, A., Grimaud, E., Raquin, M.A., Oberlin, O., Brugieres, L., Feunteun, J., Eschwege, F., Chavaudra, J., Lemerle, J. & Bonaiti-Pellie, C. (1997) Radiation and genetic factors in the risk of second malignant neoplasm after a first cancer in childhood. Lancet, 350, 9195.DOI: 10.1016/s0140-6736(97)01116-1
  • Le Beau, M.M., Albain, K.S., Larson, R.A., Vardiman, J.W., Davis, E.M., Blough, R.R., Golomb, H.M. & Rowley, J.D. (1986) Clinical and cytogenetic correlation in 63 patients with therapy-related myelodysplastic syndrome and acute nonlymphocytic leukaemia: further evidence for characteristic abnormalities of chromosome number 5 and 7. Journal of Clinical Oncology, 4, 325345.
  • Levine, E.G. & Bloomfield, C.D. (1992) Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Seminars in Oncology, 19, 4784.
  • Marx, S., Spiegel, A.M., Skarulis, M.C., Doppman, J.L., Collins, F.S. & Liotta, L.A. (1998) Multiple endocrine neoplasia type 1: clinical and genetic topics. Annals of Internal Medicine, 129, 484494.
  • Metcalf, F.D., Moore, M.A.S. & Warner, N.L. (1969) Colony formation in vitro by myelomonocytic leukaemia cells. Journal of the National Cancer Institute, 43, 9831001.
  • Najean, Y. & Rain, J.D. (1997) Treatment of polycythemia vera: the use of hydroxyurea and piproman in 292 patients under the age of 65 years. Blood, 90, 370377.
  • Neglia, J.P., Meadows, A.T., Robison, L.L., Kim, T.H., Newton, W.A., Ruymann, F.B., Sather, H.N. & Hammond, G.D. (1991) Second neoplasms after acute lymphoblastic leukaemia in childhood. New England Journal of Medicine, 325, 13301336.
  • Pagano, L., Pulsoni, A., Tosti, M.E., Annino, L., Mele, A., Camera, A., Martino, B., Guglielmi, C., Cerri, R., Di Bona, E., Invernizzi, R., Castagnola, C., Bassan, R., Mele, L., Todeschini, G., Leone, G. & Mandelli, F. (1999) Acute lymphoblastic leukaemia occurring as second malignancy. Report of GIMEMA Archive of Adult Acute leukaemia. British Journal of Haematology, 106, 10371040.
  • Panizo, C., Patino, A., Calasanz, M.J., Rifon, J., Sierrasesumaga, L. & Rocha, E. (1998) Emergence of secondary acute leukaemia in a patient treated for osteosarcoma: implications of germline TP53 mutations. Medical and Pediatric Oncology, 30, 165169.DOI: 10.1002/(sici)1096-911x(199803)30:3<165::aid-mpo7>3.0.co;2-f
  • Pedersen Bjergaard, J. & Philip, P. (1991) Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukaemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood, 78, 11471148.
  • Pedersen-Bjergaard, J. & Larsen, S.O. (1982) Incidence of acute nonlymphocytic leukaemia, preleukaemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. New England Journal of Medicine, 307, 965971.
  • Pedersen-Bjergaard, J., Pedersen, M., Roulston, D. & Philip, P. (1995) Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukaemia. Blood, 86, 35423552.
  • Philip, P. & Petersen-Bjergaard, J. (1988) Cytogenetic, clinical and cytologic characteristics of radiotherapy-related leukemias. Cancer Genetics and Cytogenetics, 31, 227236.
  • Pinto, A., Zulian, G.B. & Archibaud, E. (1998) Acute myelogenous leukaemia. Critical Review of Oncology and Hematology, 27, 161164.
  • Pottern, L.M., Linet, M., Blair, A., Dick, F., Burmeister, L.F., Gibson, R., Schuman, L.M. & Fraumeni, Jr, J.F. (1991) Familial cancers associated with subtypes of leukaemia and non-Hodgkin's lymphoma. Leukemia Research, 15, 305314.
  • Pritchard, K. (1997) Breast cancer. the real challenge. Lancet, 349, 2426.
  • Pui, C.H., Ribeiro, R.C., Hancock, M.L., Rivera, G.K., Evans, W.E., Raimondi, S.C., Head, D.R., Behm, F.G., Mahmoud, M.H., Sandlund, J.T. & Crist, W.M. (1991) Acute myeloid leukaemia in children treated with epipodophyllotoxins for acute lymphoblastic leukaemia. New England Journal of Medicine, 325, 16821687.
  • Rosenblood, B., Schreck, R. & Koffler, H.P. (1992) Therapy-related myelodysplastic syndromes. Hematology and Oncology Clinics of North America, 6, 707722.
  • Rosner, F., Carey, R.W. & Zarrabi, M.H. (1978) Breast cancer and acute leukaemia: report of 24 cases and review of the literature. American Journal of Medicine, 4, 151172.
  • Smith, M.A., McCaffrey, R.P. & Karp, J.E. (1996) The secondary leukemias: challenges and research directions. Journal of the National Cancer Institute, 88, 407418.
  • Tallman, M.S., Gray, R., Bennett, J.M., Variakojis, D., Robert, N., Wood, W.C., Rowe, J.M. & Wiernik, P.H. (1995) Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. Journal of Clinical Oncology, 13, 15571563.
  • Thirman, M.J. & Larson, R.A. (1996) Therapy-related myeloid leukaemia. Hematology and Oncology Clinics of North America, 10, 293319.
  • Valagussa, P., Moliterni, A., Terenziani, M., Zampetti, M. & Bonadonna, G. (1994) Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Annals of Oncology, 5, 803808.
  • Van Leuween, F.E., Klokmann, W.J., Hagenbeek, A., Noyon, R., Van Der Belt-dusebont, A.W., Van Kerkhoff, E.H., Van Heerde, P. & Somers, R. (1994) Second cancer risk following Hodgkin's disease: a twenty-year follow up study. Journal of Clinical Oncology, 12, 312325.
  • Vaughan, W.P., Karp, J.E. & Burke, P.J. (1983) Effective chemotherapy of acute myelocytic leukaemia occurring after alkylating agent or radiation therapy for prior malignancy. Journal of Clinical Oncology, 1, 204207.
  • Winick, N.J., McKenna, R.W., Shuster, J.J., Schneider, N.R., Borowitz, M.J., Bowman, W.P., Jacaruso, D., Kamen, B.A. & Buchanan, G.R. (1993) Secondary acute myeloid leukaemia in children with acute lymphoblastic leukaemia treated with etoposide. Journal of Clinical Oncology, 11, 209217.